Revvity, Inc. RVTY
Composite 46/100; the shares have moved about 40% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Growth ranks 22/100 — a strong mark against it.
Momentum ranks 79/100 — a strong point in its favour. Balance-sheet strength ranks 62/100 — a slight point in its favour.
Growth ranks 22/100 — a strong mark against it. Quality ranks 33/100 — a moderate mark against it. Income ranks 36/100 — a moderate mark against it.
What the company does Revvity provides health sciences solutions including instruments, reagents, software and diagnostics for early detection of conditions such as pregnancy, infectious disease and genetic disorders. Its products support genomic workflows, oncology, immunodiagnostics and drug discovery for biotech, pharma and academic labs.
Key financials Revvity’s trailing net margin is 8.2% with gross margin at 55.0%. ROE is 3.2%, ROA 2.4% and ROCE 3.3%. Revenue grew 3.7% while EPS declined -7.6%. Debt/Equity is 0.46 and net debt/EBITDA 2.65, with interest coverage 3.77 and current ratio 1.80.
Stock health Sideravia scores show weak quality (43.5) and growth (32.8) but strong momentum (79.6) and valuation percentile 36.2. Piotroski F-Score is 7/9 and Altman Z is 2.94. RSI(14) is 69.40 and the stock is -0.61% from its 52-week high.
Price vs fair value The stock is trading at a PREMIUM of 7.50% versus the analyst mean target of 121.07. - Revvity (RVTY) Stock Looks Fair On Cash Flow Yet Pricey On Earnings (2026-09-03) - Revvity (RVTY) Margins Story Faces A Valuation Test Following Its Zacks Upgrade (2026-09-02) - Revvity Faces Growth Challenges Amid Rising Competition, RBC Says (2026-09-01)
Looking forward Forward P/E is 24.39 and PEG 0.16, implying expectations for margin recovery and growth reacceleration. However, recent headlines flag margin pressure and competitive headwinds that could weigh on near-term execution.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-04, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.